Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

Past Events

May 24 - May 25, 2018

3rd Annual Advances in Immuno-Oncology Congress

London, UK

May 10, 2018 • 8:00 am ET

First Quarter 2018 Financial Results Conference Call

A replay is available until June 10, 2018, by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.

May 8, 2018 • 8:00 am ET

43rd Annual Deutsche Bank Health Care Conference

InterContinental Boston Hotel, Boston, MA

Webcast

March 20, 2018 • 11:30 am ET

Oppenheimer & Co. 28th Annual Healthcare Conference

The Westin New York Grand Central, New York, NY

Webcast

March 13, 2018 • 8:40 am ET

Cowen & Company 38th Annual Health Care Conference

The Boston Marriott Copley Place, Boston, MA

Webcast

March 9, 2018 • 8:00 am ET

Full-Year 2017 Investor Call And Corporate Update

February 22, 2018 • 3:35 pm ET

RBC Healthcare Conference

Lotte New York Palace Hotel, New York, NY

Webcast

February 15, 2018 • 3:00 pm ET

Leerink 7th Annual Global Healthcare Conference

New York, NY

February 6, 2018 • 8:00 am ET

Key Opinion Leader Event

New York, NY

Webcast

November 29, 2017 • 1:15 pm ET

Evercore ISI Biopharma Catalyst / Deep Dive Conference

Boston Harbor Hotel, Boston

More past events »

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-332 (PD1-based dual checkpoint inhibitor) as the lead program of this collaboration, to which we retain full US rights. Our pipeline also includes several programs that are developed by our partners including Roche, Daiichi Sankyo and Sanofi Aventis.

For more information about our pipeline, click here.

Upcoming Events

Past Events

Q1 2018Quarterly Results

Q4 2017Quarterly Results

Q1 2018
Quarterly Results

Q4 2017
Quarterly Results